Q&A: Novo Nordisk sustainability leader details US 'Cities,' pro cycling and more to drive diabetes awareness

Beth Snyder Bulik

Senior Editor

While the big media buzz around Novo Nordisk lately is around obesity drugs, the Denmark-based pharma is also and still the largest diabetes treatment company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A: Novo Nordisk sustainability leader details US 'Cities,' pro cycling and more to drive diabetes awareness

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Q&A: No­vo Nordisk sus­tain­abil­i­ty leader de­tails US 'C­i­ties,' pro cy­cling and more to dri­ve di­a­betes aware­ness

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Q&A: Novo Nordisk sustainability leader details US 'Cities,' pro cycling and more to drive diabetes awareness